Compare Neurocrine Biosciences Inc (NBIX) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Zillow Group Inc Class C — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Zillow Group Inc Class C trades at $32.3 (market cap $7.26B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.2× Zillow Group Inc Class C's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| NBIX | Z | |
|---|---|---|
Market Cap | $15.77B | $7.26B |
Sector | Health | Media |
52-Week High | $185.50 | $90.35 |
52-Week Low | $123.10 | $29.41 |
Enterprise Value | $15.78B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Zillow Group (Z) is trading at $32.36, down 6.45% over 24 hours, with a bearish technical signal. The stock shows mixed fundamentals: a high P/E of 139.74 reflects growth expectations, but net income margin is thin at 1.96%. Recent Q2 2026 earnings beat expectations, and revenue growth is projected from $2.6B in 2025 to $2.8B in 2026. News highlights include an FTC settlement and expansion of rental services.
The outlook is cautiously optimistic. Analyst consensus price target is $52.00, implying significant upside, but risks include a challenging housing market, ongoing profitability concerns, and recent legal settlements. The stock's current price near support at $32 suggests potential stability if fundamentals improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
